Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM
Diabetic cardiomyopathy (DCM) is one of the main complications of type 2 diabetes mellitus (T2DM), and it is also one of the main causes of heart failure and death in advanced diabetes. The myocardial lipotoxic injury induced by abnormal lipid metabolism plays an important role in the occurrence and...
Main Authors: | Zhongyuan Wang, Yunfeng Zhu, Yanhua Zhang, Jie Zhang, Tianjiao Ji, Weizu Li, Weiping Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-07-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332220302729 |
Similar Items
-
Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
by: Tan YQ, et al.
Published: (2020-09-01) -
Protective effects of Astragaloside IV on endoplasmic reticulum stress-induced renal tubular epithelial cells apoptosis in type 2 diabetic nephropathy rats
by: Yinghui Ju, et al.
Published: (2019-01-01) -
Astragaloside IV Ameliorates Myocardial Infarction Induced Apoptosis and Restores Cardiac Function
by: Chuang Sun, et al.
Published: (2021-07-01) -
Astragaloside IV alleviates lipopolysaccharide‐induced preeclampsia‐like phenotypes via suppressing the inflammatory responses
by: Dilihuma Tuerxun, et al.
Published: (2021-03-01) -
Astragaloside IV Alleviates Liver Inflammation, Oxidative Stress and Apoptosis to Protect Against Experimental Non-Alcoholic Fatty Liver Disease
by: Liang XY, et al.
Published: (2021-04-01)